Phaseline

Companies › Marker Therapeutics

Marker Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MT-601
Multi-antigen specific CD4+ and CD8+ T cells
–Phase 1Non-Hodgkin Lymphoma, AdultFeb 2028
MT-401-OTS
off-the-shelf allogeneic T-cell therapy
–Phase 1Acute Myeloid Leukemia, in RelapseSep 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05798897MT-601Phase 1Non-Hodgkin Lymphoma, AdultOncologyFeb 2028
NCT06552416MT-401-OTSPhase 1Acute Myeloid Leukemia, in RelapseOncologySep 2029

From the company's SEC filings

Cash of $11m on 2026-06-30; operating cash outflow about $10m a year; runway about 13 months at that burn, to Aug 2027

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.